Bezos-Buffett-Dimon venture looks to cut out drug distributors

Getty Images (l) | CNBC (c-r)

Jeff Bezos, Warren Buffett and Jamie Dimon.

The newly announced health-care venture from Jeff Bezos, Warren Buffett, and Jamie Dimon could render any deal between Walgreens Boots Alliance and AmerisourceBergen useless.

CNBC’s Jim Cramer said Tuesday, according to sources, that Bezos’ Amazon, Buffett’s Berkshire Hathaway, and Dimon’s J.P. Morgan aim to cut out drug distributors like Amerisource, Cardinal Health, and McKesson.

“Jeff Bezos believes he can lower the price of health care,” Cramer said on “Squawk on the Street.” “He can become even more dominant and really eviscerate some of the competitors.”

“[Walgreens] may not be as smart as they think they are” considering Amerisource, Cramer said. “These companies are going to be squeezed by that [Bezos] venture and squeezed by others that have to compete.”

Late Monday, The Wall Street Journal reported that Walgreens approached Amerisource about buying the three-quarters of the firm it doesn’t already own. Amerisource shares skyrocketed more than 25 percent after-hours Monday, and were up about 10 percent Tuesday morning.

Despite being a possibly risky move for Walgreens, Cramer said it’s a great time for Amerisource to sell itself.

“I would sell” because Amazon “wants to cut out the middleman,” said Cramer, the host of “Mad Money.”

None of the companies mentioned was immediately available to respond to CNBC’s request for comment.